CCN3: A novel anti-fibrotic treatment in end-stage renal disease?

Journal of Cell Communication and Signaling

Volumn 6, Issue 2, 2012, Pages 115-116

  Leask, Andrew ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

CCN2; CCN3; Connective tissue growth factor; Diabetes; Fibrosis; Nov; PDGF

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; NEPHROBLASTOMA OVEREXPRESSED PROTEIN;

ALBUMINURIA; ALLERGIC GLOMERULONEPHRITIS; ANGIOGENESIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; GLOMERULOSCLEROSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84863109665     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0162-6     Document Type: Article

References (17)

1. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5(8):1420-1428
2. Di Paolo S, Gesualdo L, Ranieri E, Grandaliano G, Schena FP (1996) High glucose concentration induces the overexpression of transforming growth factor-β through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol 149:2095-2106 (Pubitemid 26415226)
3. Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19:12-23
4. Kawaki H, Kubota S, Suzuki A, Suzuki M, Kohsaka K, Hoshi K, Fujii T, Lazar N, Ohgawara T, Maeda T, Perbal B, Takano-Yamamoto T, Takigawa M (2011) Differential roles of CCN family proteins during osteoblast differentiation: involvement of Smad and MAPK signaling pathways. Bone 49(5):975-989
5. Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318:1657-1666
6. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME (2005) Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16:363-373 (Pubitemid 41725131)
7. Leask A (2009) Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal 3(2):161-162
8. Mason RM (2009) Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 3(2):95-104
9. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H (1993) mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450-456 (Pubitemid 23066522)
10. Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC (2009) CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174(5):1725-1734
11. Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC, Peterson DR (2010) CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal 4 (1):39-50
12. Twigg SM (2010) Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease. J Cell Commun Signal 4(4):189-196
13. van Roeyen CR, Eitner F, Scholl T, Boor P, Kunter U, Planque N, Grone HJ, Bleau AM, Perbal B, Ostendorf T, Floege J (2008) CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73:86-94 (Pubitemid 350273638)
14. van Roeyen CR, Eitner F, Boor P, Moeller MJ, Raffetseder U, Hanssen L, Bücher E, Villa L, Banas MC, Hudkins KL, Alpers CE, Ostendorf T, Floege J (2011) Induction of progressive glomerulonephritis by podocyte-specific overexpression of plateletderived growth factor-D. Kidney Int. 80(12):1292-305
15. van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, Kaitovic A, Fleckendstein S, Perbal B, Trautwein C, Weishirchen R, Ostendorf T, Floege J (2012) A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and anti-mesangioproliferative effects. Am J Pathol, in press
16. Wolf G (2002) Molecular mechanisms of diabetic mesangial cell hypertrophy: a proliferation of novel factors. J Am Soc Nephrol 13:2611-2613
17. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020 (Pubitemid 30460765)